Skip to main content
Clinical Trials/NCT03632174
NCT03632174
Completed
Not Applicable

Clinical Study for the Evaluation and Comparison of Cutaneous Acceptability and the Efficacy of 2 Cosmetic Products, Under Normal Conditions of Use, in Adult Participants With Atopic Dermatitis

BioGaia AB1 site in 1 country36 target enrollmentJanuary 21, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atopic Dermatitis
Sponsor
BioGaia AB
Enrollment
36
Locations
1
Primary Endpoint
Appraisal of Cutaneous acceptability of the investigational products by dermatologist investigator
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The study consists in the application of 2 investigational products (one group per investigational product) under normal conditions of use, in adult participants with Atopic Dermatitis.

It is carried out on cosmetic products, with the aim to further confirm safety of these products

Detailed Description

Probiotics are live micro-organisms which when administered in adequate amounts can exert a health benefit on the host. This health-promoting effects of Lactobacillus reuteri have been extensively studied in the gastrointestinal tract but it is clear that other areas are also interesting for the use of probiotics. Atopic Dermatitis is a relapsing inflammatory skin disease appearing on persons with a genetic predisposition of allergic pathology. AD generally starts in childhood, however in some cases can continue into adult hood, in at least 10% of cases. AD can effect a persons quality of life and in the chronic stage it can present with dry skin and lichenification. Research has shown that probiotics have an antimicrobial, anti-inflammatory and barrier function effect, and could therefore be used on subjects with Atopic Dermatitis to relieve and protect.

Registry
clinicaltrials.gov
Start Date
January 21, 2019
End Date
October 16, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
BioGaia AB
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participant has not been on a course of long term treatment in particular with aspirin, products containing aspirin, anti-inflammatories, antibiotics, antihistamines, corticoids
  • Participant presenting with mild to moderate atopic dermatitis according to the definition of the UK Working Party's Diagnostic Criteria for Atopic Dermatitis (SCORAD index \>25)
  • Participant presenting with a current lesion of Atopic Dermatitis on defined area

Exclusion Criteria

  • Participant is pregnant, breast feeding or not willing to take the necessary precautions to avoid pregnancy during the study
  • Participant having background of intolerance or allergy
  • Participant not respecting the washout period during which a person may not be involved in any other biomedical research projects
  • Participant having skin exposed to sunlight within 2 weeks preceding the inclusion
  • Participant having modified his/her cosmetic habits during the last two weeks

Outcomes

Primary Outcomes

Appraisal of Cutaneous acceptability of the investigational products by dermatologist investigator

Time Frame: 4 weeks

Cutaneous acceptability is assessed on the basis of clinical examination of the skin for physical signs (erythema, oedema, dryness) linked to the use of the investigational product and also evaluation the functional signs (prickling, tightness, heating)

Secondary Outcomes

  • Change in Local SCORAD index(baseline, at 4, and 8 weeks)
  • Change in SCORAD index over 8 week period(baseline, at 4 and 8 weeks)

Study Sites (1)

Loading locations...

Similar Trials